Leerink partners began its role as the lead book-running manager for an offering on behalf of BlossomHill Therapeutics, Inc. on August 1, 2026.
1 report, 1 independent
Updated Aug 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Leerink partners began its role as the lead book-running manager for an offering on behalf of BlossomHill Therapeutics, Inc. on August 1, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Leerink partners
U.S. investment bank
Related events
- Leerink Partners is a joint bookrunning manager for an offering by Retension Pharmaceuticals, Inc., with the prospectus available from Boston, MA.
- Leerink Partners is acting as a placement agent for First Tracks Biotherapeutics.
- Kazia Therapeutics Limited is seeking joint bookrunning management and co-management for a proposed offering, with Leerink partners and Needham & Company involved.
- Leerink Partners, Cantor Fitzgerald, and Barclays acted as placement agents for Atrium on October 8, 2026.